Image Place holder

Hyo Han, MD


Specialty: Medical Oncology
Program: Breast Oncology

Call 1-888-MOFFITT
(1-888-663-3488)

Call 1-888-MOFFITT
(1-888-663-3488)


Locations: Moffitt McKinley Outpatient Center
Overview

Cancer Focus: Breast Cancer, Ductal Carcinoma In Situ , Inflammatory Breast Cancer , Invasive Ductal Carcinoma , Triple Negative Breast Cancer

Dr. Heather Han is the Research Director and medical oncologist in the Moffitt Cancer Center Department of Breast Oncology. She is dedicated to helping find a cure for the millions of women whose lives have been affected by a diagnosis of breast cancer. Dr. Han finds that Moffitt Cancer Center offers a unique health care environment in that outstanding physicians in every discipline work together for a common cause in the battle against cancer.  She believes that the future of cancer is to provide personalized treatment for every patient.  Moffitt’s Total Cancer Care initiative is making great strides toward this goal. Dr. Han is currently researching outcomes among breast cancer patients of different nationalities, including Asian, African American, Hispanic and Caucasian, to determine whether race may have an impact on disparities in chemotherapy toxicity.  She is also a principal investigator for phase one and phase two clinical trials evaluating novel targeted breast cancer therapies designed to improve prognosis, reduce side-effects and improve quality of life.  Dr. Han enjoys the opportunity to participate in Moffitt’s medical oncology fellowship program, serving as an instructor and mentor for the outstanding medical oncologists of the future.

Education & Training

Board Certification:

  • Medical Oncology
  • Hematology
  • Internal Medicine

Fellowship:

  • University of Miami/Jackson Memorial Hospital - Hematology/Oncology

Residency:

  • Cleveland Clinic Foundation - Internal Medicine

Medical School:

  • Seoul University College of Medicine - MD
Participating Trials

CLINICAL TRIAL 17268
I-SPY 2 TRIAL (Investigation of Serial Studies to Predict Your Therapeutic Response with Imaging And moLecular Analysis 2)
Condition: Breast
Intervention:
Open

CLINICAL TRIAL 19117
A Multicenter Phase II Study of Vaccines to Prevent Recurrence in Patients with HER-2 Positive Breast Cancer
Condition: Breast
Intervention:
Open

CLINICAL TRIAL 18979
Phase II Open-Label, Randomized Study of PARP inhibition (Olaparib) Either Alone or in Combination with Anti-PD-L1 Therapy (Atezolizumab; MPDL3280A) in Homologous DNA Repair (HDR) Deficient, Locally Advanced or Metastatic Non-HER2-positive Breast Cancer
Condition: Breast
Intervention: Atezolizumab (Tecentriq); Olaparib (Lynparza)
Open

CLINICAL TRIAL 18936
A Phase I-II Study of Interferon-gamma Plus Weekly Paclitaxel, Trastuzumab and Pertuzumab in Patients with HER-2 Positive Breast Cancer
Condition: Breast
Intervention: Herceptin (Trastuzumab); Pertuzumab (); Taxol (paclitaxel); Trastuzumab (); interferon gamma (Actimmune); paclitaxel (); rhuMAb HER2 (Trastuzumab)
Open

CLINICAL TRIAL 20171
A Phase 1, Open-label, Dose Escalation Clinical Trial to Evaluate the Safety, Tolerability and Pharmacokinetics of ARV-471 in Patients with ER+/HER2- Locally Advanced or Metastatic Breast Cancer, Who Have Received Prior Hormonal Therapy and Chemotherapy in the Locally Advanced/Metastatic Setting
Condition: Breast
Intervention: ARV-471 ()
Open

CLINICAL TRIAL 19603
Single Arm, Open Label Phase 1b/2 Study of SGN-LIV1A in Combination with Pembrolizumab for First-Line Treatment of Patients with Unresectable Locally-Advanced or Metastatic Triple-Negative Breast Cancer
Condition: Breast
Intervention: Pembrolizumab (Keytruda); SGN-LIV1A ()
Open

If you believe you are eligible for one of these trials or studies, please call
813-745-6100 or toll-free 1-800-679-0775.

Publications

  • Figura NB, Rizk VT, Armaghani AJ, Arrington JA, Etame AB, Han HS, Czerniecki BJ, Forsyth PA, Ahmed KA. Breast leptomeningeal disease: a review of current practices and updates on management. Breast Cancer Res Treat. 2019 Sep;177(2):277-294. Pubmedid: 31209686.
  • Tan AR, Wright GS, Thummala AR, Danso MA, Popovic L, Pluard TJ, Han HS, Vojnović Ž, Vasev N, Ma L, Richards DA, Wilks ST, Milenković D, Yang Z, Antal JM, Morris SR, O'Shaughnessy J. Trilaciclib plus chemotherapy versus chemotherapy alone in patients with metastatic triple-negative breast cancer: a multicentre, randomised, open-label, phase 2 trial. Lancet Oncol. 2019 Sep.20(11):1587-1601. Pubmedid: 31575503.
  • Figura NB, Rizk VT, Mohammadi H, Evernden B, Mokhtari S, Yu HM, Robinson TJ, Etame AB, Tran ND, Liu J, Washington I, Diaz R, Czerniecki BJ, Soliman H, Han HS, Sahebjam S, Forsyth PA, Ahmed KA. Clinical outcomes of breast leptomeningeal disease treated with intrathecal trastuzumab, intrathecal chemotherapy, or whole brain radiation therapy. Breast Cancer Res Treat. 2019 Jun.175(3):781-788. Pubmedid: 30859348.
  • Shafique M, Ismail-Khan R, Extermann M, Sullivan D, Goodridge D, Boulware D, Hogue D, Soliman H, Khong H, Han HS. A Phase II Trial of Selinexor (KPT-330) for Metastatic Triple-Negative Breast Cancer. Oncologist. 2019 Jul;24(7):887-e416. Pubmedid: 30996012. Pmcid: PMC6656474.
  • Costa R, Zaman S, Sharpe S, Helenowski I, Shaw C, Han H, Soliman H, Czerniecki B. A brief report of toxicity end points of HER2 vaccines for the treatment of patients with HER2 breast cancer. Drug Des Devel Ther. 2019 Jan;13:309-316. Pubmedid: 30679903. Pmcid: PMC6338114.
  • Figura NB, Potluri TK, Mohammadi H, Oliver DE, Arrington JA, Robinson TJ, Etame AB, Tran ND, Liu JK, Soliman H, Forsyth PA, Sahebjam S, Yu HM, Han HS, Ahmed KA. CDK 4/6 inhibitors and stereotactic radiation in the management of hormone receptor positive breast cancer brain metastases. J Neurooncol. 2019 Aug;144(3):583-589. Pubmedid: 31399935.
  • B Figura N, Long W, Yu M, Robinson TJ, Mokhtari S, Etame AB, Tran ND, Diaz R, Soliman H, S Han H, Sahebjam S, Forsyth PA, Ahmed KA. Intrathecal trastuzumab in the management of HER2+ breast leptomeningeal disease: a single institution experience. Breast Cancer Res Treat. 2018 Jun;169(2):391-396. Pubmedid: 29392582.
  • Ahmed KA, Grass GD, Orman AG, Liveringhouse C, Montejo ME, Soliman HH, Han HS, Czerniecki BJ, Torres-Roca JF, Diaz R. Personalizing Radiation Treatment Delivery in the Management of Breast Cancer. Int J Breast Cancer. 2018 Jun.2018:6729802. Pubmedid: 29984003. Pmcid: PMC6015692.
  • Han HS, Diéras V, Robson M, Palácová M, Marcom PK, Jager A, Bondarenko I, Citrin D, Campone M, Telli ML, Domchek SM, Friedlander M, Kaufman B, Garber JE, Shparyk Y, Chmielowska E, Jakobsen EH, Kaklamani V, Gradishar W, Ratajczak CK, Nickner C, Qin Q, Qian J, Shepherd SP, Isakoff SJ, Puhalla S. Veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in patients with BRCA1/2 locally recurrent/metastatic breast cancer: randomized phase II study. Ann Oncol. 2018 Jan;29(1):154-161. Pubmedid: 29045554. Pmcid: PMC5834075.
  • Soliman H, Khambati F, Han HS, Ismail-Khan R, Bui MM, Sullivan DM, Antonia S. A phase-1/2 study of adenovirus-p53 transduced dendritic cell vaccine in combination with indoximod in metastatic solid tumors and invasive breast cancer. Oncotarget. 2018 Feb.9(11):10110-10117. Pubmedid: 29515795. Pmcid: PMC5839376.
  • Pistilli B, Pluard T, Urruticoechea A, Farci D, Kong A, Bachelot T, Chan S, Han HS, Jerusalem G, Urban P, Robinson D, Mouhaër SL, Tomaso ED, Massacesi C, Saura C. Phase II study of buparlisib (BKM120) and trastuzumab in patients with HER2+ locally advanced or metastatic breast cancer resistant to trastuzumab-based therapy. Breast Cancer Res Treat. 2018 Apr;168(2):357-364. Pubmedid: 29198055.
  • Reich RR, Lengacher CA, Alinat CB, Kip KE, Paterson C, Ramesar S, Han HS, Ismail-Khan R, Johnson-Mallard V, Moscoso M, Budhrani-Shani P, Shivers S, Cox CE, Goodman M, Park J. Mindfulness-Based Stress Reduction in Post-treatment Breast Cancer Patients: Immediate and Sustained Effects Across Multiple Symptom Clusters. J Pain Symptom Manag. 2017 Jan;53(1):85-95. Pubmedid: 27720794.
  • Isakoff SJ, Puhalla S, Domchek SM, Friedlander M, Kaufman B, Robson M, Telli ML, Diéras V, Han HS, Garber JE, Johnson EF, Maag D, Qin Q, Giranda VL, Shepherd SP. A randomized Phase II study of veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in BRCA1/2 metastatic breast cancer: design and rationale. Future Oncol. 2017 Feb;13(4):307-320. Pubmedid: 27739325. Pmcid: PMC5618936.
  • Chow LW, Biganzoli L, Leo AD, Kuroi K, Han HS, Patel J, Huang CS, Lu YS, Zhu L, Chow CY, Loo WT, Glück S, Toi M. Toxicity profile differences of adjuvant docetaxel/cyclophosphamide (TC) between Asian and Caucasian breast cancer patients. Asia Pac J Clin Oncol. 2017 Dec;13(6):372-378. Pubmedid: 28371190.
  • Soliman HH, Minton SE, Han HS, Ismail-Khan R, Neuger A, Khambati F, Noyes D, Lush R, Chiappori AA, Roberts JD, Link C, Vahanian NN, Mautino M, Streicher H, Sullivan DM, Antonia SJ. A phase I study of indoximod in patients with advanced malignancies. Oncotarget. 2016 Apr;7(16):22928-22938. Pubmedid: 27008709. Pmcid: PMC5008412.
  • Rosa M, Han HS, Ismail-Khan R, Allam-Nandyala P, Bui MM. Beta-catenin expression patterns in matched pre- and post-neoadjuvant chemotherapy-resistant breast cancer. Ann Clin Lab Sci. 2015 Dec;45(1):10-16. Pubmedid: 25696004.
  • Malo TL, Lipkus I, Wilson T, Han HS, Acs G, Vadaparampil ST. Treatment Choices Based on OncotypeDx in the Breast Oncology Care Setting. J Cancer Epidemiol. 2012 Aug;2012:941495. Pubmedid: 22927848. Pmcid: PMC3425834.
  • Han HS, Reis IM, Zhao W, Kuroi K, Toi M, Suzuki E, Syme R, Chow L, Yip AY, Glück S. Racial differences in acute toxicities of neoadjuvant or adjuvant chemotherapy in patients with early-stage breast cancer. Eur J Cancer. 2011 Nov;47(17):2537-2545. Pubmedid: 21741825.
  • Lee MC, Gray J, Han HS, Plosker S. Fertility and reproductive considerations in premenopausal patients with breast cancer. Cancer Control. 2010 Jul;17(3):162-172. Pubmedid: 20664513.
  • Biagioli MC, Harvey M, Roman E, Raez LE, Wolfson AH, Mutyala S, Han HS, Markoe A. Intensity-modulated radiotherapy with concurrent chemotherapy for previously irradiated, recurrent head and neck cancer. Int J Radiat Oncol Biol Phys. 2007 Nov;69(4):1067-1073. Pubmedid: 17967302.
  • Han H, Rybicki L, Thiel K, Kalaycio M, Sobecks R, Advani A, Brown S, Sekeres M. White blood cell count nadir following remission induction chemotherapy is predictive of outcome in older adults with acute myeloid leukemia. Leuk Lymphoma. 2007 Aug;48(8):1561-1568. Pubmedid: 17701588.